MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria

Abstract

Philadelphia chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders of the bone marrow, and are associated with a high disease burden, reduced quality of life (QOL), and shortened survival. This multinational, multicenter, non-interventional registry "MERGE" was initiated with an objective to collect data on the epidemiological indices of classical Ph-MPNs, existing treatment patterns, and impact of MPNs on health-related QOL in various countries/regions in Asia, including the Middle East, Turkey, and Algeria.Of the 884 eligible patients with MPNs, 169 had myelofibrosis (MF), 301 had polycythemia vera (PV), 373 had essential thrombocythemia (ET), and 41 had unclassified MPNs. The median age was 58 years (range, 47-66 years), and 50% of patients were males. The prevalence and incidence of MPNs were estimated to be 57-81 and

Extreme Levels of Platelet Count in Essential Thrombocythemia: Management and Outcome, Report of Two Cases

“…Triple-negative, no JAK2, CALR, or MPL mutation, is present in around 10-15%. There are rare cases that have mutations in the thrombopoietin gene (THPO), which are associated with autosomal dominant hereditary thrombocytosis, and somatic mutations in TET methylcytosine dioxygenase 2 (TET2) [5][6][7][8]. The median age at diagnosis is around 60 years, although as many as 20% may be younger than 40 years of age [9].…”

Chronic Myeloid Leukemia Preceded by Tuberculosis

“…Exposure to ionizing radiation is the only known risk factor for CML [4]. Tyrosine kinase inhibitors are a cornerstone in the management of CML around the world with good results [5][6][7][8][9]. This case is shedding light on a possible association between TB and the development of CML.…”

COVID19 infection revealed chronic myeloid leukemia in chronic phase: A case report

“…In Our case the presentation of COVID 19 was associated with CML at the time of presentation; however we believe that this association is only a coincidence and any abnormal results during this pandemic should be taken seriously as it can harbor more grim disease. This patient was started on imatinib 400 mg daily as upfront therapy for CML treatment does not need to be changed depending on COVID 19 status and he was discharged with regular follow up as per ASH recommendations 2020 9 .…”